CERETEC

This brand name is authorized in United States. It is also authorized in Austria, Cyprus, France, Hong Kong SAR China, Ireland, Lithuania, Malta, Singapore, Spain, UK.

Active ingredients

The drug CERETEC contains one active pharmaceutical ingredient (API):

1	Technetium ⁹⁹ᵐTc exametazime UNII G29272NCKL - EXAMETAZIME
	When technetium Tc 99m pertechnetate is added to exametazime in the presence of stannous reductant, a lipophilic technetium Tc 99m complex is formed. This lipophilic complex is the active moiety. The lipophilic technetium Tc 99m exametazime complex is taken up and retained in leukocytes. It is used for leukocyte (white blood cell) labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease.
	Read more about Technetium ⁹⁹ᵐTc exametazime

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CERETEC Powder for solution for injection	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V09AA01	Technetium (99mTc) exametazime	V Various → V09 Diagnostic radiopharmaceuticals → V09A Central nervous system → V09AA Technetium (99mTc) compounds
Discover more medicines within V09AA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ES	Centro de información online de medicamentos de la AEMPS	61024, 62666
FR	Base de données publique des médicaments	64378030
GB	Medicines & Healthcare Products Regulatory Agency	398447, 398450
HK	Department of Health Drug Office	42837
LT	Valstybinė vaistų kontrolės tarnyba	1014235, 1014240
MT	Medicines Authority	AA023/00601
SG	Health Sciences Authority	11825P
US	FDA, National Drug Code	17156-022